Filtered By:
Condition: Fatty Liver Disease (FLD)
Nutrition: High Fat
This page shows you your search results in order of date.
Order by Relevance | Date
Total 59 results found since Jan 2013.
Chaperonin counteracts diet-induced non-alcoholic fatty liver disease by aiding sirtuin 3 in the control of fatty acid oxidation
Conclusion/interpretationMitochondrial HSP60 promotes fatty acid oxidation while repressing mitochondrial stress and inflammation to ameliorate the development of NAFLD by preserving SIRT3 signalling. This study reveals the hepatoprotective effects of HSP60 and indicates that HSP60 could play a fundamental role in the development of therapeutics for NAFLD or type 2 diabetes.Graphical abstract
Source: Diabetologia - March 24, 2023 Category: Endocrinology Source Type: research
Caveolin-1 ameliorates acetaminophen-aggravated inflammatory damage and lipid deposition in non-alcoholic fatty liver disease via the ROS/TXNIP/NLRP3 pathway
Int Immunopharmacol. 2023 Jan;114:109558. doi: 10.1016/j.intimp.2022.109558. Epub 2022 Dec 21.ABSTRACTThe overuse of acetaminophen (APAP) may cause more severe hepatotoxicity in patients with non-alcoholic fatty liver disease (NAFLD). Caveolin-1 (CAV1), is an essential regulator of metabolic function, which can alleviate liver damage by scavenging reactive oxygen species (ROS). Evidence suggests that the NOD-like receptor family pyrin domain-containing 3 (NLRP3) -mediated pyroptosis is involved in the development of NAFLD. Moreover, thioredoxin-interactive protein (TXNIP) activation is a key event linking ROS to NLRP3 infl...
Source: International Immunopharmacology - January 26, 2023 Category: Allergy & Immunology Authors: Xiangfu Jiang Yu Li Dongdong Fu Tingyu You Shuai Wu Jiao Xin Jiagen Wen Yan Huang Chengmu Hu Source Type: research
GSE222499 Liver-specific FGFR4 knockdown in mice on a HFD increases bile acid synthesis and improves hepatic steatosis II
Contributor : Softic SamirSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusNonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease with increased risk in patients with metabolic syndrome. There are no FDA approved treatments, but farnesoid X receptor (FXR) agonists have shown promising results in clinical studies for NAFLD management. In addition to FXR, fibroblast growth factor receptor FGFR4 is a key mediator of hepatic bile acid synthesis. Using N-acetylgalactosamine-conjugated siRNA, we knocked down FGFR4 specifically in the liver of mice on chow or...
Source: GEO: Gene Expression Omnibus - January 11, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
Dnmt1/Tet2-mediated changes in Cmip methylation regulate the development of nonalcoholic fatty liver disease by controlling the Gbp2-Ppar γ-CD36 axis
Exp Mol Med. 2023 Jan 6. doi: 10.1038/s12276-022-00919-5. Online ahead of print.ABSTRACTDynamic alteration of DNA methylation leads to various human diseases, including nonalcoholic fatty liver disease (NAFLD). Although C-Maf-inducing protein (Cmip) has been reported to be associated with NAFLD, its exact underlying mechanism remains unclear. Here, we aimed to elucidate this mechanism in NAFLD in vitro and in vivo. We first identified alterations in the methylation status of the Cmip intron 1 region in mouse liver tissues with high-fat high-sucrose diet-induced NAFLD. Knockdown of DNA methyltransferase (Dnmt) 1 significant...
Source: Molecular Medicine - January 7, 2023 Category: Molecular Biology Authors: Jangho Lee Ji-Hye Song Jae-Ho Park Min-Yu Chung Seung-Hyun Lee Sae-Bom Jeon So Hee Park Jin-Taek Hwang Hyo-Kyoung Choi Source Type: research
Caveolin-1 alleviates acetaminophen-induced vascular oxidative stress and inflammation in non-alcoholic fatty liver disease
In conclusion, our findings confirmed that CAV1 exerts a protective effect against vascular injury by inhibiting oxidative stress and inflammation through the PKC/MAPK pathway. Therefore, restoration of CAV1 may have clinical benefits in reducing APAP-induced vascular damage in NAFLD patients.PMID:36596386 | DOI:10.1016/j.freeradbiomed.2022.12.095
Source: Free Radical Biology and Medicine - January 3, 2023 Category: Biology Authors: Dongdong Fu Shuai Wu Xiangfu Jiang Tingyu You Yu Li Jiao Xin Xiaowen Feng Jiagen Wen Yan Huang Chengmu Hu Source Type: research
Induction of autophagy via the PI3K/Akt/mTOR signaling pathway by Pueraria flavonoids improves non-alcoholic fatty liver disease in obese mice
Biomed Pharmacother. 2022 Nov 13;157:114005. doi: 10.1016/j.biopha.2022.114005. Online ahead of print.ABSTRACTNon-alcoholic fatty liver disease (NAFLD) is the most common among lipid metabolism disorders. Autophagy plays an important role in lipid metabolism in NAFLD. Pueraria flavonoids, the main active ingredients of Pueraria lobata, exert antioxidant and anti-inflammatory effects. Herein, we report the potential lipid-lowering and anti-inflammatory effects of Pueraria flavonoids on NAFLD induced by a high-fat diet. In vivo and in vitro experiments showed that Pueraria flavonoids reduced intracellular lipid deposition by...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - November 16, 2022 Category: Drugs & Pharmacology Authors: Chunbin Sun Jin Zhang Jiong Hou Menglin Hui Hualong Qi Tong Lei Xiaoshuang Zhang Luxi Zhao Hongwu Du Source Type: research
Baicalin improved hepatic injury of NASH by regulating NRF2/HO-1/NRLP3 pathway
This study indicates that baicalin is able to attenuate hepatic cell pyroptosis in vivo and in vitro in the case of NASH by regulating the NRF2/HO-1/NRLP3 pathway.PMID:36184988 | DOI:10.1016/j.ejphar.2022.175270
Source: European Journal of Pharmacology - October 3, 2022 Category: Drugs & Pharmacology Authors: Huilian Shi Fei Qiao Weiting Lu Kaiyue Huang Yuanyuan Wen Lifang Ye Yuanyuan Chen Source Type: research
